PubMed | Rosemere Cancer Center
Type: Journal Article | Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Year: 2016
1126 Background: Capecitabine is increasingly used in the treatment of metastatic breast cancer (MBC). We evaluated the use of capecitabine therapy (XT) in MBC at our centre, to determine factors that might predict response.We reviewed the records of patients (pts) with MBC who received XT, from February 05 to March 06. The duration of XT, whether use was continuous or intermittent, the line of use and concurrent treatments were evaluated. Response to XT was correlated to potential predicitve factors including age, tumour grade, estrogen receptor (ER) status and HER2 expression. Time to progression (TTP) and overall survival (OS) after XT were calculated.Seventy-two women received XT with a median age at initiation of 57 years. At diagnosis, 44% had grade 3 tumors. ER was positive in 61% and HER2 over-expressed in 33%. Adjuvant chemotherapy was given to 61% and adjuvant hormones to 54%. Median time to first relapse was 29 months (mths). XT was used commonly as 2nd- (26.4%) or 3rd-line (30.6%) treatment after relapse. XT was continuous in 83% and intermittent in 17%. Median number of XT cycles was 4 (range: 1-37). An objective response was noted in 23% and the overall clinical benefit rate was 43% (partial/good responses plus stable disease). The only positive correlation to predict response was ER positivity (p = 0.04). Common significant toxicity included grade 2, palmo-plantar erythema (22%) and fatigue (15%). In 22% a dose modification or delay was necessary. XT was stopped in 5 pts due to toxicity. Median OS after XT was 12 mths (95% CI 6.87-17.13) and median TTP on XT 3 mths (95% CI 2.07-3.93).XT remains an important palliative treatment option for patients with MBC. Patients with ER positive tumours respond better to XT. We did not identify any other factor that predicted response to XT. [Table: see text].